Adherence to entecavir for chronic hepatitis B and correlation with effectiveness
Purpose: to evaluate adherence of patients with chronic hepatitis B initiated on entecavir as first-line treatment and to correlate adherence with effectiveness. Methods: observational retrospective study performed between January 2007 and June 2013. Patients treated with entecavir for at least one...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2015-11-01
|
| Series: | Farmacia Hospitalaria |
| Subjects: | |
| Online Access: | http://www.aulamedica.es/fh/pdf/8374.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850037794555035648 |
|---|---|
| author | Vanessa Romero Díaz-Maroto Marina Sánchez Cuervo Miguel Ángel Rodríguez Sagrado Teresa Bermejo Vicedo |
| author_facet | Vanessa Romero Díaz-Maroto Marina Sánchez Cuervo Miguel Ángel Rodríguez Sagrado Teresa Bermejo Vicedo |
| author_sort | Vanessa Romero Díaz-Maroto |
| collection | DOAJ |
| description | Purpose: to evaluate adherence of patients with chronic hepatitis B initiated on entecavir as first-line treatment and to correlate adherence with effectiveness. Methods: observational retrospective study performed between January 2007 and June 2013. Patients treated with entecavir for at least one year were included. A patient was considered to be adherent if median adherence was ≥ 95%. Virological response (HBV DNA < 20UI/ml by Polymerase Chain Reaction), biochemical response (normalized level of alanine amino transferase [AAT]) and serological response (loss of hepatitis B surface antigen [HBsAg]) was assessed at month 12. Results: 85 patients were included. The median adherence rate was 94.2 (SD 12.8)%. 85.7% of the adherent patients achieved a virological response in contrast with 71.4% of the nonadherent patients (OR:2,40; IC95%:0,60–9,54;p = 0,19). 87.9% of the adherent patients and 85.7% of the nonadherent patients showed normalized level of AAT (OR:1,21; IC95%:0,22- 6,60;p = 0,56). Two adherent patients showed clearance of hepatitis B surface antigen. Conclusion: the median adherence is not high. Nonadherent patients have a trend towards a higher rate of virological failure so it is necessary to promote improved adherence to treatment |
| format | Article |
| id | doaj-art-44a4fa3d176a4f23bf7bade6f9206f4a |
| institution | DOAJ |
| issn | 1130-6343 2171-8695 |
| language | English |
| publishDate | 2015-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Farmacia Hospitalaria |
| spelling | doaj-art-44a4fa3d176a4f23bf7bade6f9206f4a2025-08-20T02:56:46ZengElsevierFarmacia Hospitalaria1130-63432171-86952015-11-0139637838110.7399/fh.2015.39.6.8374Adherence to entecavir for chronic hepatitis B and correlation with effectivenessVanessa Romero Díaz-Maroto0Marina Sánchez Cuervo1Miguel Ángel Rodríguez Sagrado2Teresa Bermejo Vicedo3Servicio de Farmacia. Hospital Universitario Ramón y Cajal, Madrid. España.Servicio de Farmacia. Hospital Universitario Ramón y Cajal, Madrid. España.Servicio de Farmacia. Hospital Universitario Ramón y Cajal, Madrid. España.Servicio de Farmacia. Hospital Universitario Ramón y Cajal, Madrid. España.Purpose: to evaluate adherence of patients with chronic hepatitis B initiated on entecavir as first-line treatment and to correlate adherence with effectiveness. Methods: observational retrospective study performed between January 2007 and June 2013. Patients treated with entecavir for at least one year were included. A patient was considered to be adherent if median adherence was ≥ 95%. Virological response (HBV DNA < 20UI/ml by Polymerase Chain Reaction), biochemical response (normalized level of alanine amino transferase [AAT]) and serological response (loss of hepatitis B surface antigen [HBsAg]) was assessed at month 12. Results: 85 patients were included. The median adherence rate was 94.2 (SD 12.8)%. 85.7% of the adherent patients achieved a virological response in contrast with 71.4% of the nonadherent patients (OR:2,40; IC95%:0,60–9,54;p = 0,19). 87.9% of the adherent patients and 85.7% of the nonadherent patients showed normalized level of AAT (OR:1,21; IC95%:0,22- 6,60;p = 0,56). Two adherent patients showed clearance of hepatitis B surface antigen. Conclusion: the median adherence is not high. Nonadherent patients have a trend towards a higher rate of virological failure so it is necessary to promote improved adherence to treatmenthttp://www.aulamedica.es/fh/pdf/8374.pdfHepatitis B; Chronic; EntecavirEffectiveness;Medication adherence |
| spellingShingle | Vanessa Romero Díaz-Maroto Marina Sánchez Cuervo Miguel Ángel Rodríguez Sagrado Teresa Bermejo Vicedo Adherence to entecavir for chronic hepatitis B and correlation with effectiveness Farmacia Hospitalaria Hepatitis B ; Chronic ; Entecavir Effectiveness; Medication adherence |
| title | Adherence to entecavir for chronic hepatitis B and correlation with effectiveness |
| title_full | Adherence to entecavir for chronic hepatitis B and correlation with effectiveness |
| title_fullStr | Adherence to entecavir for chronic hepatitis B and correlation with effectiveness |
| title_full_unstemmed | Adherence to entecavir for chronic hepatitis B and correlation with effectiveness |
| title_short | Adherence to entecavir for chronic hepatitis B and correlation with effectiveness |
| title_sort | adherence to entecavir for chronic hepatitis b and correlation with effectiveness |
| topic | Hepatitis B ; Chronic ; Entecavir Effectiveness; Medication adherence |
| url | http://www.aulamedica.es/fh/pdf/8374.pdf |
| work_keys_str_mv | AT vanessaromerodiazmaroto adherencetoentecavirforchronichepatitisbandcorrelationwitheffectiveness AT marinasanchezcuervo adherencetoentecavirforchronichepatitisbandcorrelationwitheffectiveness AT miguelangelrodriguezsagrado adherencetoentecavirforchronichepatitisbandcorrelationwitheffectiveness AT teresabermejovicedo adherencetoentecavirforchronichepatitisbandcorrelationwitheffectiveness |